Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Sjogren's Syndrome

In brief

The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).

Key facts

Study ID
NCT03100942
Run by
Gilead Sciences
People needed
152
Starts
2017-05-01
Expected to finish
2019-10-02
Last updated by the study team
2020-10-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.